Rapport Therapeutics (RAPP) Research & Development (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Research & Development data on file, last reported at $32.7 million in Q1 2026.

• On a quarterly basis, Research & Development rose 67.16% year-over-year to $32.7 million in Q1 2026; TTM through Mar 2026 was $107.9 million, a 58.72% increase from a year earlier, with the FY2025 full-year figure at $94.8 million, up 55.56% from the prior year.
• Research & Development for Q1 2026 stood at $32.7 million, up from $30.3 million in the prior quarter.
• Over the last five years, Research & Development for RAPP reached as high as $32.7 million in Q1 2026 and fell as low as $4.7 million in Q2 2023.
• Historically, Research & Development has averaged $17.7 million across 4 years, with a median of $16.4 million in 2024.
• Across the five-year window, Research & Development soared 232.32% in 2024 and surged 43.34% in 2025, its largest moves.
• Year by year, Research & Development stood at $11.8 million in 2023, then jumped by 45.77% to $17.2 million in 2024, then surged by 75.93% to $30.3 million in 2025, then gained by 8.12% to $32.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $32.7 million in Q1 2026, $30.3 million in Q4 2025, and $22.3 million in Q3 2025.